Lab Scale Manufacturing Using Continuous Crystallization
News Apr 15, 2014
In the webinar, in situ Process Analytical Technology (PAT) supported the development of a continuous plug flow crystallization platform that was able to meet production scale capacities in a lab setting while tightly controlling product attributes including particle size and shape distribution as well as yield and purity.
The Company is pleased to present a new installment in its thought-leading on-demand webinar series on Process Analytical Technology (PAT). The presentation, entitled “PAT-Based Design of Continuous Crystallizations,” explores specific methodology using ParticleTrack with Focused Beam Reflectance Measurement (FBRM) technology and related technologies for rapid plug-flow crystallization evaluation. Experiments using this methodology enabled a significant increase in production volume on lab-scale equipment.
Guest presenter Steven Ferguson, Biogen Idec, Cambridge, Massachusetts, developed the experiment series while working on his PhD as part of the Glennon Research Group (SSPC) at University College, Dublin. He also spent time at Novartis/ MIT Center for Continuous Manufacturing and Department of Chemical Engineering, as a post-doctoral associate with a focus on continuous crystallization, isolation and polymorphism.
A plug flow crystallization platform was developed that allowed PAT to be applied in situ via the use of novel flow cells to develop the anti-solvent crystallization of benzoic acid from aqueous ethanol solution. Equivalent tank-based MSMPR crystallizations using a pneumatic slurry transfer were also characterized using PAT. Both methods were then compared to equivalent batch crystallizations to gain their true performance measure.
As expected, continuous crystallization offered significantly intensified production, with approximately the same material generated by ~33 ml plug flow, 9 L MSMPR, and 42, 10,000 L batch crystallizations per annum. Furthermore, non-batch processing enabled production of a wider range of particle sizes and morphologies, with plug flow generating the highest possible supersaturation when feed and anti-solvent streams were perfectly mixed.
Despite its relatively small volume, under optimum conditions the plug flow device proved capable of producing 60 kilos a day of dry, isolated benzoic acid, providing production-scale pharmaceutical development with lab-scale equipment. Screening methodologies to determine if plug flow crystallization is appropriate for a particular chemistry is also explored, as is using FBRM and Particle Vision Microscopy (PVM) to monitor and maximize operating conditions.
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
10th Edition of International Conference on Structural Biology 2018
Mar 15 - Mar 17, 2018
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017